Precigen’s PAPZIMEOS Demonstrates 83% Response at 36 Months and Seven-Year Exclusivity
PGEN•PAPZIMEOS achieved ongoing complete responses in 15 of 18 patients (83%) at 36 months, with five patients sustaining responses beyond four years and median duration not yet reached. The US FDA granted seven-year orphan drug exclusivity to PAPZIMEOS, and no new safety events were observed during long-term follow-up.
1. Durable Response Rates
PAPZIMEOS achieved ongoing complete responses in 15 of 18 patients (83%) at a minimum follow-up of 36 months, with five patients maintaining responses beyond four years and the median duration not reached.
2. Safety Profile
Long-term follow-up revealed no new adverse safety events among complete responders, reinforcing the therapy’s favorable tolerability over an average follow-up of 40 months.
3. Regulatory Exclusivity
The US FDA granted seven-year orphan drug market exclusivity to PAPZIMEOS, securing its position as the sole approved therapy for adult recurrent respiratory papillomatosis.
4. RRP Market Overview
An internal analysis estimates approximately 27,000 adult RRP patients in the US, highlighting significant unmet need and potential market opportunity for a durable, non-surgical treatment.
